[ { "id": "rituximab-count", "group": "B-cell depletion", "title": "Rituximab: platelet counts after a four-dose course", "kind": "Count trajectory", "population": "Adults with chronic/refractory ITP; 18 treated with 375 mg/m² weekly for four doses.", "interpretation": "Curves are grouped by response category, not randomized dose. The image labels them means, whereas the article text calls them medians. The month labels are unequally spaced in time but equally spaced on the plot; do not estimate slopes from visual distance.", "license": "Publisher copyright; no explicit open reuse licence identified on the retrieved article.", "article_title": "Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis", "author": "Jaime Garcia-Chavez", "publication_date": "2007 Sep 14", "doi": "10.1007/s00277-007-0317-3", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2040174/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2040174/figure/Fig1/", "source_figure": "Fig1", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de6/2040174/c1f5f99bf68a/277_2007_317_Fig1_HTML.jpg", "file": "rituximab-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "10519bfe5786d811cbf57eda2856d6c298c89a21af70a965699b4a8bbd8c4e83" }, { "id": "rituximab-duration", "group": "B-cell depletion", "title": "Rituximab: years of response after treatment", "kind": "Response-duration context", "population": "Selected initial responders; adult inclusion required response lasting at least one year.", "interpretation": "These response-survival projections incorporate published first-year response estimates, followed by the selected cohort’s longer follow-up. They are not platelet counts or a single all-treated cohort. Adult and pediatric selection differs.", "license": "Publisher copyright; no explicit open reuse licence identified on the retrieved article.", "article_title": "Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia", "author": "Vivek L Patel", "publication_date": "2012 May 7", "doi": "10.1182/blood-2011-11-393975", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3383014/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3383014/figure/F2/", "source_figure": "F2", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6b/3383014/d03e8b5fd0f5/zh89991292890002.jpg", "file": "rituximab-duration.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "54e82e2b4040c68a0218add25926e542907a1575ce8e8019a8a028efcf435da8" }, { "id": "rituximab-recovery", "group": "B-cell depletion", "title": "Rituximab: B-cell recovery alongside the durability question", "kind": "Immune-recovery context", "population": "B-cell trajectories in a selected subset of initial ITP responders.", "interpretation": "B-cell recovery in selected initial responders accompanies the durability analysis. The plotted count scale and printed unit need reconciliation before digitization. The association does not establish a dose effect or distinguish naive-cell recovery from pathogenic-cell return.", "license": "Publisher copyright; no explicit open reuse licence identified on the retrieved article.", "article_title": "Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia", "author": "Vivek L Patel", "publication_date": "2012 May 7", "doi": "10.1182/blood-2011-11-393975", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3383014/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3383014/figure/F3/", "source_figure": "F3", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a6b/3383014/86f44263405e/zh89991292890003.jpg", "file": "rituximab-recovery.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "b9f9f0e7d7f3b33857e9a0dde4d036a15febee018c68f932dc7fd38fe40e774d" }, { "id": "romiplostim-count", "group": "TPO pathway", "title": "Romiplostim: platelet counts through 24 weeks", "kind": "Count trajectory", "population": "Routine-practice adult cohort, separated by disease duration at treatment initiation.", "interpretation": "Unweighted medians show longitudinal counts; interpret the medians alongside follow-up availability and dose titration. Disease-phase groups are not randomized regimens.", "license": "Reuse licence not resolved from the retrieved article; consult source copyright notice.", "article_title": "Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany", "author": "Marcel Reiser", "publication_date": "2021 Dec 27", "doi": "10.1159/000521689", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9393823/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9393823/figure/F4/", "source_figure": "F4", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e597/9393823/0f0c221e9c78/aha-0145-0394-g04.jpg", "file": "romiplostim-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "18bde8a4216a1a4d2aef7284b7c5896fc46589beb7e51b491dcbb9c13948b5b1" }, { "id": "romiplostim-dose", "group": "TPO pathway", "title": "Romiplostim: the dosing trajectory behind those counts", "kind": "Dose context", "population": "Same routine-practice cohort as the platelet plot above.", "interpretation": "Mean weekly dose helps interpret the apparent count plateau. Response-guided dosing means exposure is partly a consequence of earlier counts.", "license": "Reuse licence not resolved from the retrieved article; consult source copyright notice.", "article_title": "Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany", "author": "Marcel Reiser", "publication_date": "2021 Dec 27", "doi": "10.1159/000521689", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9393823/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9393823/figure/F3/", "source_figure": "F3", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e597/9393823/6b7bfa84f21c/aha-0145-0394-g03.jpg", "file": "romiplostim-dose.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "845d18e0eca672ce0e2851681f9e47ee3630ff9e91a3a42508d5acb32647a10a" }, { "id": "avatrombopag-count", "group": "TPO pathway", "title": "Avatrombopag: early rise, core study and extension", "kind": "Count trajectory", "population": "Randomized adult chronic-ITP study, starting at 20 mg/day; core study and open-label extension.", "interpretation": "Medians and quartiles retain spread. Read the numbers observed and the change to the extension population; later values do not represent an unchanged randomized cohort.", "license": "CC BY-NC 4.0", "article_title": "Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia", "author": "Wojciech Jurczak", "publication_date": "2018 Sep 7", "doi": "10.1111/bjh.15573", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6282556/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6282556/figure/bjh15573-fig-0003/", "source_figure": "bjh15573-fig-0003", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/431d/6282556/5838d11aab44/BJH-183-479-g003.jpg", "file": "avatrombopag-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "84d2e51caa5d68dd47bf030259206fce8d1d254e0a9d755d9875cc178c4d6f52", "license_url": "https://creativecommons.org/licenses/by-nc/4.0/" }, { "id": "eltrombopag-rhtpo-count", "group": "TPO pathway", "title": "Eltrombopag versus dose-optimized recombinant TPO", "kind": "Count trajectory", "population": "TE-ITP randomized active-comparator study in adults.", "interpretation": "Mean counts with standard errors show a direct within-study comparison. The interventions are treatment strategies with dose management, not equivalent fixed doses.", "license": "CC BY 4.0", "article_title": "Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)", "author": "Yunfei Chen", "publication_date": "2025 Aug 21", "doi": "10.1016/j.eclinm.2025.103459", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12396493/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12396493/figure/fig3/", "source_figure": "fig3", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed64/12396493/00b611db84a1/gr3.jpg", "file": "eltrombopag-rhtpo-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "7cf41d2ea37de8e5e171c850278767bab0ef7eba88933d620a2a213edd5ba0aa", "license_url": "https://creativecommons.org/licenses/by/4.0/" }, { "id": "pediatric-comparison", "group": "TPO pathway", "title": "Rituximab, TPO-RAs and oral immunosuppressants in children", "kind": "Count trajectory at discrete visits", "population": "ICON1 prospective observational study of children starting second-line therapy.", "interpretation": "This source image is panel A alone. Medians are shown at baseline (triangles), 1 month (squares), 6 months (circles), and 12 months (diamonds). Treatment assignment was not randomized; pediatric results should not be substituted for adult ITP.", "license": "Author manuscript; no explicit open reuse licence identified on the retrieved article.", "article_title": "Second-Line Treatments in Children with Immune Thrombocytopenia: Effect on Platelet Count and Patient-Centered Outcomes", "author": "Rachael F Grace", "publication_date": "2019 Apr 29", "doi": "10.1002/ajh.25479", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6527349/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6527349/figure/F1/", "source_figure": "Figure 1A", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26eb/6527349/5fb22d5da01c/nihms-1022047-f0001.jpg", "file": "pediatric-comparison.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "a85cce35a5872ed253a7a68a905d4439e1e1f569293a4b8cde4fbb8f643ba04e" }, { "id": "ivig-count", "group": "Rapid immunomodulation", "title": "IVIg: early rise and subsequent decline", "kind": "Count trajectory", "population": "Panzyga chronic-ITP study; full analysis set of 36 patients.", "interpretation": "A short-timescale platelet course useful for recognizing a rescue-treatment contribution. ET denotes early termination, not a common scheduled late timepoint.", "license": "CC BY 4.0", "article_title": "Efficacy and safety of a new intravenous immunoglobulin (Panzyga®) in chronic immune thrombocytopenia", "author": "O Arbach", "publication_date": "2019 Jan 27", "doi": "10.1111/tme.12573", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6850321/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6850321/figure/tme12573-fig-0001/", "source_figure": "tme12573-fig-0001", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec6f/6850321/05fd4d2a545f/TME-29-48-g001.jpg", "file": "ivig-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "46f2b51807ae710dbfba429de5092c45319ed7c74d22151dbca7cf6c7bafd624", "license_url": "https://creativecommons.org/licenses/by/4.0/" }, { "id": "ivig-antid-individual", "group": "Rapid immunomodulation", "title": "IVIg and anti-D: repeated individual treatment episodes", "kind": "Individual count trajectory with production marker", "population": "Selected patients with repeated anti-D or IVIg treatment episodes.", "interpretation": "Platelets and absolute immature platelet counts are shown together. Within-patient recurrence is informative, but selected examples are not a population response distribution.", "license": "Publisher copyright; no explicit open reuse licence identified on the retrieved article.", "article_title": "Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia", "author": "Sarah J Barsam", "publication_date": "2011 Mar 9", "doi": "10.1182/blood-2010-11-321398", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3110029/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3110029/figure/F4/", "source_figure": "F4", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8ca/3110029/0f94bc04cfad/zh89991170390004.jpg", "file": "ivig-antid-individual.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "7b82b6fbf2b8b7e9ce85c8735b526a55ab5116379b3520c048d7a000d75d5d97" }, { "id": "steroid-persistence", "group": "Corticosteroids", "title": "Dexamethasone followed by prednisone: persistence of response", "kind": "Response-duration context", "population": "Newly diagnosed adults treated with high-dose dexamethasone followed by prednisone maintenance.", "interpretation": "Response-survival curves among initial responders, not raw platelet trajectories. This combination cannot isolate a four-day dexamethasone effect; an early platelet-count figure remains a requested addition.", "license": "CC BY-NC 4.0", "article_title": "Clinical efficacy of high-dose dexamethasone with sequential prednisone maintenance therapy for newly diagnosed adult immune thrombocytopenia in a real-world setting", "author": "Jin Xu", "publication_date": "2021 Apr 12", "doi": "10.1177/03000605211007322", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8044565/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8044565/figure/fig2-03000605211007322/", "source_figure": "fig2-03000605211007322", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd3/8044565/a805e5740078/10.1177_03000605211007322-fig2.jpg", "file": "steroid-persistence.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "8ae4a2417008112a48028e49bd09270cdaf14dd3cab79083b3e4d461588a3193", "license_url": "https://creativecommons.org/licenses/by-nc/4.0/" }, { "id": "efgartigimod-count-igg", "group": "FcRn inhibition", "title": "Efgartigimod: platelets and IgG on the same timeline", "kind": "Count trajectory with IgG and bleeding", "population": "Randomized Phase 2 ITP study comparing placebo and 5 or 10 mg/kg, with four weekly infusions.", "interpretation": "Circles show mean platelets and triangles the IgG readout; arrows mark infusions. The caption calls IgG a percentage change, but the plotted baseline is near 100; check that convention before extracting values. Post-rescue observations are excluded.", "license": "CC BY-NC-ND 4.0", "article_title": "Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia", "author": "Adrian C Newland", "publication_date": "2019 Dec 10", "doi": "10.1002/ajh.25680", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7004056/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7004056/figure/ajh25680-fig-0002/", "source_figure": "ajh25680-fig-0002", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36e8/7004056/8d514c9a4386/AJH-95-178-g002.jpg", "file": "efgartigimod-count-igg.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "ce9a864c995b0f856491172469f2815d3ec849f721f70099f37eb47c88fe8102", "license_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/" }, { "id": "rozanolixizumab-count", "group": "FcRn inhibition", "title": "Rozanolixizumab: placebo-controlled periods and extension", "kind": "Count trajectory", "population": "Two randomized ITP studies and their open-label extension.", "interpretation": "Mean counts and SD are shown with sample sizes. Post-rescue observations are excluded; extension dosing schedules and participants differ from the blinded periods.", "license": "CC BY 4.0", "article_title": "Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension", "author": "Nichola Cooper", "publication_date": "2024 Nov 18", "doi": "10.1111/bjh.19858", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11829145/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11829145/figure/bjh19858-fig-0001/", "source_figure": "bjh19858-fig-0001", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769d/11829145/83149cb486c6/BJH-206-675-g001.jpg", "file": "rozanolixizumab-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "6b01761c33cb8a0c97b2953340be269bbcb55b967d88e6f95402a8367afa746e", "license_url": "https://creativecommons.org/licenses/by/4.0/" }, { "id": "rilzabrutinib-count", "group": "Signalling inhibitors", "title": "Rilzabrutinib: overall and responder-conditioned trajectories", "kind": "Count trajectory with subgroup analysis", "population": "LUNA3 randomized adult persistent/chronic-ITP trial; 400 mg twice daily versus placebo.", "interpretation": "Panels A and B show medians and IQR. Continuation after week 12 depended on response, and panel B conditions on response status; late separation is not a simple fixed-cohort exposure effect.", "license": "CC BY-NC-ND 4.0", "article_title": "Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study", "author": "David J Kuter", "publication_date": "2025 Mar 18", "doi": "10.1182/blood.2024027336", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12824683/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12824683/figure/fig2/", "source_figure": "fig2", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7ce/12824683/024472567e4b/BLOOD_BLD-2024-027336-gr2.jpg", "file": "rilzabrutinib-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "ab4c022583466e1b125dc276ef355296d89a751c2dae9f9508b14275db9f4b0d", "license_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/" }, { "id": "fostamatinib-count", "group": "Signalling inhibitors", "title": "Fostamatinib: platelet trajectories by response classification", "kind": "Count trajectory", "population": "Pooled FIT1/FIT2 trials; starting 100 mg twice daily, with escalation to 150 mg twice daily in nonresponders.", "interpretation": "Both panels condition on response classification. The week-12 boundary permits nonresponders to enter extension; these are not unselected randomized-arm medians throughout.", "license": "CC BY-NC 4.0", "article_title": "Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials", "author": "James Bussel", "publication_date": "2018 May 15", "doi": "10.1002/ajh.25125", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6055608/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6055608/figure/ajh25125-fig-0002/", "source_figure": "ajh25125-fig-0002", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ff/6055608/11d026a80bce/AJH-93-921-g002.jpg", "file": "fostamatinib-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "f4a3bef87552900cf6b73dd4addb9b07fc8b1d9c48c52f354d3987ee2ec5ec0d", "license_url": "https://creativecommons.org/licenses/by-nc/4.0/" }, { "id": "fostamatinib-duration", "group": "Signalling inhibitors", "title": "Fostamatinib: patient-level treatment and response duration", "kind": "Response-duration context", "population": "Selected second-line fostamatinib responders.", "interpretation": "Swimmer lanes separate treatment duration from maintained response. Nonresponders are omitted, so this is a view of heterogeneity among responders rather than response probability.", "license": "CC BY-NC-ND 4.0", "article_title": "Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia", "author": "Ralph Boccia", "publication_date": "2020 Jul 23", "doi": "10.1111/bjh.16959", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7540289/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7540289/figure/bjh16959-fig-0002/", "source_figure": "bjh16959-fig-0002", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e2/7540289/716864147a9c/BJH-190-933-g002.jpg", "file": "fostamatinib-duration.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "518d8a4cd26cfeaaab06ffb0fefe5873b8b2a797f039f0c6722c801555dc238e", "license_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/" }, { "id": "cm313-count", "group": "Plasma-cell targeting", "title": "CM313 anti-CD38: early platelet trajectory", "kind": "Count trajectory", "population": "Randomized Phase 2 trial in adults with persistent/chronic primary ITP.", "interpretation": "The downloaded static figure shows the first 14 days of least-squares mean platelet counts with SE bands. The labels at the top are tabs in the interactive original, not additional panels in this JPEG; use the interactive link for the 24-week and response-proportion views.", "license": "CC BY-NC 4.0", "article_title": "Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial", "author": "Yunfei Chen", "publication_date": "2025 Oct 21", "doi": "10.1136/bmj-2025-084314", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12538382/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12538382/figure/f2/", "source_figure": "f2", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd93/12538382/f6d45e2e83bf/chey084314.f2.jpg", "file": "cm313-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "interactive_url": "https://public.flourish.studio/visualisation/25195771/", "sha256": "964e4dbaa98fbb6678b8cf380ac62c6a3c7391230c3b87ab330e7ef3c7cf1995", "license_url": "https://creativecommons.org/licenses/by-nc/4.0/" }, { "id": "cm313-duration", "group": "Plasma-cell targeting", "title": "CM313 anti-CD38: response patterns for individual patients", "kind": "Response-duration context", "population": "Same CM313 trial; individual lanes include response categories and concomitant treatment.", "interpretation": "Each row follows one patient through 24 weeks; colours classify response and larger dots mark rescue. Post-rescue data are classified as nonresponse, with one patient’s later status omitted. The article caption describes red bars, but the static image uses coloured dots; use its visible legend.", "license": "CC BY-NC 4.0", "article_title": "Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial", "author": "Yunfei Chen", "publication_date": "2025 Oct 21", "doi": "10.1136/bmj-2025-084314", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12538382/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12538382/figure/f3/", "source_figure": "f3", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd93/12538382/6ecf79ed1d82/chey084314.f3.jpg", "file": "cm313-duration.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "interactive_url": "https://public.flourish.studio/visualisation/25276109/", "sha256": "5a34f3ee5c65087b327be2b542c633d59727233296a62b1a8e7f83834a093e27", "license_url": "https://creativecommons.org/licenses/by-nc/4.0/" }, { "id": "splenectomy-count", "group": "Splenectomy", "title": "Splenectomy: early rise and one-year follow-up", "kind": "Count trajectory", "population": "Retrospective cohort including primary and secondary ITP, grouped by postsplenectomy TPO-RA use.", "interpretation": "Box plots show baseline, 1 and 4 weeks, and 3, 6 and 12 months. TPO-RA use was related to inadequate response; the groups do not estimate a randomized TPO-RA effect. Time intervals are unequal.", "license": "CC BY-NC-ND 4.0", "article_title": "Beyond platelet counts: assessing safety of postsplenectomy TPO-RA use in ITP", "author": "Ruah Alyamany", "publication_date": "2025 Sep 4", "doi": "10.1182/bloodadvances.2025017902", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12666339/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12666339/figure/fig4/", "source_figure": "fig4", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10af/12666339/823df0395d30/BLOODA_ADV-2025-017902-gr4.jpg", "file": "splenectomy-count.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "c3ae8dce8ad746ede8c633a688b2008e4ce87b0d873691f1dfac112397affbc5", "license_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/" }, { "id": "splenectomy-individual", "group": "Splenectomy", "title": "Splenectomy in children: individual platelet trajectories", "kind": "Individual count trajectories", "population": "Pediatric international registry of splenectomy in ITP.", "interpretation": "Individual curves show the first 30 days and approximately 50 months. The blue line is a loess smooth, not a representative patient. Large early peaks and differing late courses illustrate what a group summary hides.", "license": "CC BY-NC 4.0", "article_title": "Long-term outcomes after splenectomy in children with immune thrombocytopenia: an update on the registry data from the Intercontinental Cooperative ITP Study Group", "author": "Maria L Avila", "publication_date": "2019 Dec 19", "doi": "10.3324/haematol.2019.236737", "article_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7604652/", "figure_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7604652/figure/fig001/", "source_figure": "fig001", "image_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b1/7604652/c5f90dd0b360/1052682.fig1.jpg", "file": "splenectomy-individual.jpg", "retrieved": "2026-09-14", "image_changes": "None; original source JPEG; browser scales display only.", "sha256": "d99ed403b19d0da7eb834daf0dffea244b82d79108b58b6a283ea6497262e27d", "license_url": "https://creativecommons.org/licenses/by-nc/4.0/" } ]